Literature DB >> 12624783

Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin.

Y Matsumura1, T Hori, C Nishigori, K Shirogane, K-I Toda, T Uchiyama, Y Tanaka, Y Miyachi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12624783     DOI： 10.1007/s00403-002-0363-6

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  5 in total

1.  Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis.

Authors:  Ruru Guo; Ting Zhang; Xinyu Meng; Zhen Lin; Jinran Lin; Yu Gong; Xuesong Liu; Yuetian Yu; Guilin Zhao; Xianting Ding; Xiaoxiang Chen; Liangjing Lu
Journal:  JCI Insight       Date:  2019-03-21

2.  Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Authors:  Michael J Gough; Marka R Crittenden; MaryClare Sarff; Puiyi Pang; Steven K Seung; John T Vetto; Hong-Ming Hu; William L Redmond; John Holland; Andrew D Weinberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

3.  Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Authors:  Michael J Gough; N Killeen; Andrew D Weinberg
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

4.  OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.

Authors:  Ichiyo Shibahara; Ryuta Saito; Rong Zhang; Masashi Chonan; Takuhiro Shoji; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Masahiko Kanehira; Toshiaki Kikuchi; Takanori So; Takashi Watanabe; Hiroaki Takahashi; Erina Iwabuchi; Yuetsu Tanaka; Yukiko Shibahara; Hironobu Sasano; Naoto Ishii; Teiji Tominaga
Journal:  Mol Cancer       Date:  2015-02-15       Impact factor: 27.401

5.  Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.

Authors:  K A Papp; M J Gooderham; G Girard; M Raman; V Strout
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-06-14       Impact factor: 6.166
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.